



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: carglumic acid

Page: 1 of 3

Effective Date: 4/25/2025

Last Review Date: 4/4/2025

Applies to: Illinois
 Florida Kids

New Jersey
 Pennsylvania Kids

Maryland
 Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for carglumic acid under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Acute Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency

Carbaglu is indicated in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. During acute hyperammonemic episodes, concomitant administration of Carbaglu with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and dietary protein restriction is recommended.

Chronic Hyperammonemia due to N-acetylglutamate Synthase (NAGS) Deficiency

Carbaglu is indicated in pediatric and adult patients as maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels.

Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)

Carbaglu is indicated in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to PA or MMA.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

carglumic acid

Policy/Guideline:

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

Initial requests:

- Enzyme assay, biochemical, or genetic testing results supporting diagnosis.
- Lab results documenting baseline plasma ammonia levels.

Continuation of therapy requests:

- Lab results documenting a reduction in plasma ammonia levels from baseline



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: carglumic acid

Page: 2 of 3

Effective Date: 4/25/2025

Last Review Date: 4/4/2025

Applies to: Illinois
 Florida Kids

New Jersey
 Pennsylvania Kids

Maryland
 Virginia

Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of enzyme or metabolic disorders

Criteria for Initial Approval:

N-acetylglutamate Synthase (NAGS) Deficiency

Authorization of 12 months may be granted for members with a diagnosis of NAGS deficiency when BOTH the following criteria are met:

- The diagnosis is confirmed by enzymatic, biochemical, or genetic testing.
- The member has elevated plasma ammonia levels at baseline.

Methylmalonic Acidemia

Authorization of 12 months may be granted for members with a diagnosis of methylmalonic acidemia when BOTH the following criteria are met:

- The diagnosis is confirmed by enzymatic, biochemical, or genetic testing.
- The member has elevated plasma ammonia levels at baseline.

Propionic Acidemia

Authorization of 12 months may be granted for members with a diagnosis of propionic acidemia when BOTH the following criteria are met:

- The diagnosis is confirmed by enzymatic, biochemical, or genetic testing.
- The member has elevated plasma ammonia levels at baseline

Criteria for Continuation of Therapy:

N-acetylglutamate Synthase (NAGS) Deficiency, Methylmalonic Acidemia, or Propionic Acidemia

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for NAGS deficiency, methylmalonic acidemia, or propionic acidemia who are experiencing benefit from therapy as evidenced by a decrease in ammonia levels from baseline and disease stability or disease improvement

Approval Duration and Quantity Restrictions:

Initial and Renewal Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Carbaglu [package insert]. Lebanon, NJ: Recordati Rare Diseases, Inc.; January 2024.
2. Filippi L, Gozzini E, Fiorini P, et al. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. *Neonatology*. 2010;97(3):286-290.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: carglumic acid

Page: 3 of 3

Effective Date: 4/25/2025

Last Review Date: 4/4/2025

Applies to: Illinois New Jersey Maryland
 Florida Kids Pennsylvania Kids Virginia

3. Levrat V, Forest I, Fouilhoux A, et al. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia. *Orphanet J Rare Dis.* 2008;3:2.
4. Gebhardt B, Vlaho S, Fischer D, et al. N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. *Mol Genet Metab.* 2003;79(4):303-304.
5. Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. *J Interit Metab Dis.* 2005;28(2):241-244.
6. Schwahn BC, Pletterse L, Bisset WM, et al. Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidemia. *Eur J Pediatr.* 2010;169(1):133-134.
7. Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. *Orphanet J Rare Dis.* 2016;11:32.
8. Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. *Orphanet J Rare Dis.* 2014; 9:130.
9. carglumic acid [package insert]. Deer Park, IL; Eton Pharmaceuticals, Inc.; January 2024.